Systemic Sclerosis Clinical Trial
— FACEOfficial title:
EFFECTS OF THE MICRO REINJECTION OF AUTOLOGOUS ADIPOSE TISSUE IN THE FACE OF PATIENTS WITH SYSTEMIC SCLEROSIS
This prospective single-center study evaluates a current care procedure. It includes 14
patients diagnosed with SSc according to the ACR/EULAR criteria or the Leroy & Medsger
criteria of the disease. Patients are enrolled if they wish for a therapeutic care of their
face, have a Mouth Handicap in Systemic Sclerosis (MHISS) score greater than 20 (scale
0-48), a modified Rodnan skin score upper or equal to 1 on the face (scale 0-3), and a mouth
opening less than 55 millimeters. They should not have anticoagulant, anti-platelets
aggregation medication or a daily steroid dose upper 20mg per day. Their BMI should exceed
17.
Micro fat grafting is a minimally invasive and usual procedure performed under local
anesthesia. Fat tissue is harvested (around 50 milliliters) using a 14 gauge or 2 mm
diameter cannula from areas around the knees, the abdomen or the hips under a gentle
aspiration. Lipoaspirated fat is then filtrated by the PureGraft system that offers a
sterile, closed, single-use system, leading to a fast, consistent and controlled
preparation. Then, 10 to 25 milliliters of this purified fat product is transferred through
a 21 gauge or 0.8 mm diameter cannula in two or four points of the face, with the entry
points located around the mouth.
Status | Recruiting |
Enrollment | 15 |
Est. completion date | November 2015 |
Est. primary completion date | November 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Patients older than 18 or younger than 80 years. - Suffering from systemic scleroderma. - Patient follow-AP-HM. - Score of 20 or greater MHISS. - Score Rodnan level greater than or equal to one face. - Mouth opening (inter-incisor distance) <5.5 cm - Wishing to receive surgery at the face. Exclusion Criteria: - Less than 18 or greater than 80 age. - Decaying history of abdominal surgery. - Body mass index lower than 18. - Coagulation disorders. - Allergy to Xylocaine. - Greater than 20mg / d steroids. - Severe infection. - Inmates. - Pregnant women. - Adults protected by law (under guardianship and trusteeship). - No affiliation to a social security scheme. |
Intervention Model: Single Group Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
France | Assistance Publique Hopitaux de Marseille | Marseille |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique Hopitaux De Marseille |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | improvement of the MHISS score | The MHISS questionnaire is chosen as it specifically assesses disability involving the mouth and the face in SSc patients. | 12 months | No |
Secondary | evaluate the effect of the procedure on quality of life | Health Assessment Questionnaire adapted to scleroderma, SHAQ | 12 months | No |
Secondary | evaluate the effect of the procedure on face pain | face pain scale (VAS 0-100) | 12 months | No |
Secondary | evaluate the effect of the procedure on skin fibrosis | skin fibrosis is measured by Rodnan skin score for the face, mouth opening measure and cutometry) | 12 months | No |
Secondary | evaluate the effect of the procedure on physical face changes | physical face changes is evaluated by standard and 3D photographs. | 12 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03274076 -
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
|
Phase 1/Phase 2 | |
Completed |
NCT04300426 -
Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue)
|
Phase 2 | |
Recruiting |
NCT06058091 -
RY_SW01 Cell Injection Therapy in Systemic Sclerosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04356755 -
Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma.
|
Phase 2 | |
Suspended |
NCT06210945 -
Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis
|
Phase 2 | |
Not yet recruiting |
NCT05947682 -
Manufacturing of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells for Treatment of Severe Systemic Sclerosis
|
N/A | |
Not yet recruiting |
NCT05177380 -
Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis
|
N/A | |
Not yet recruiting |
NCT04303208 -
Sirtuin 3 and Sirtuin 7 in Systemic Sclerosis
|
N/A | |
Recruiting |
NCT02551042 -
CSL Behring Sclero XIII
|
Phase 2 | |
Terminated |
NCT02243111 -
Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound
|
N/A | |
Terminated |
NCT02246348 -
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
|
N/A | |
Completed |
NCT01933334 -
Safety and Tolerability of Pirfenidone in Patients With Systemic SclerosisâRelated Interstitial Lung Disease (SSc-ILD) (LOTUSS)
|
Phase 2 | |
Completed |
NCT01468792 -
Hemodynamic Changes in Connective Tissue Disease
|
N/A | |
Terminated |
NCT00848107 -
Open-Label Study of Oral Treprostinil in Digital Ulcers
|
Phase 2 | |
Completed |
NCT00984932 -
Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT00074568 -
Scleroderma Registry
|
||
Not yet recruiting |
NCT06412614 -
Evaluation of Patients With Systemic Sclerosis Without Specific or Associated Autoantibodies
|
||
Terminated |
NCT00622687 -
Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis
|
Phase 2 | |
Recruiting |
NCT04464434 -
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 4 | |
Recruiting |
NCT04246528 -
SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)
|
N/A |